SCHEMBL24988965

SCHEMBL24988965

CCC(C)c1nc2c(=O)n(C)c(=O)nc-2n(C(C)C)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 12/20 0.45
POLB P06746 3/20 0.45
MAPT P10636 3/20 0.45
RAB9A P51151 3/20 0.45
GALK1 P51570 3/20 0.45
BLM P54132 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPSR1 Q6W5P4 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
NPC1 O15118 2/20 0.45
ABL1 P00519 2/20 0.45
MPI P34949 2/20 0.45
RIN1 Q13671 2/20 0.45
ATG4B Q9Y4P1 2/20 0.45
KDM4E B2RXH2 2/20 0.45
THRB P10828 2/20 0.45
HTT P42858 2/20 0.45
PTPN22 Q9Y2R2 2/20 0.45
RECQL P46063 1/20 0.45
DUSP3 P51452 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24989323 0.86 TDP2 (0.58) TDP2POLBMAPTRAB9AGALK1
SCHEMBL24989324 0.70 POLB (0.34) TDP2POLBMAPTRAB9AGALK1
SCHEMBL18608692 0.70 L3MBTL1 (0.33) L3MBTL1
SCHEMBL3473947 0.70 TDP2 (0.65) TDP2POLBMAPTRAB9AGALK1
SCHEMBL3474309 0.64 TDP2 (0.46) TDP2MAPTRAB9ASMN1; SMN2NPSR1
SCHEMBL2180811 0.64 TDP2 (0.77) TDP2POLBMAPTRAB9AGALK1
SCHEMBL14450329 0.62 HSF1 (0.48) TDP2POLBMAPTRAB9AGALK1
SCHEMBL2180986 0.62 TDP2 (1.00) TDP2POLBMAPTRAB9AGALK1
SCHEMBL15032586 0.62 TDP2 (1.00) TDP2POLBMAPTRAB9AGALK1
SCHEMBL13272699 0.60 TDP2 (0.70) TDP2POLBMAPTRAB9AGALK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
EP-4129282-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TCF4, TCF7L2, CTNNB1 TDP2 2515/4885POLB 254/4885MAPT 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.